Cáncer de riñón con metástasis a colon. Un sitio poco frecuente de metástasis

Valdespino-Castillo, Víctor Edmundo; Ruiz-Jaime, Alejandro
July 2008
Cirugia y Cirujanos;jul/ago2008, Vol. 76 Issue 4, p339
Academic Journal
Background: Renal cancers represent ~3% of malignant tumors in adults and occur in a M:F ratio (1.5:1.0). Although in most cases it occurs in persons 50 to 70 years of age, there are also reports in children. Clear cell carcinoma is the most frequent histological type and 30% of renal carcinomas have metastasized at the time of diagnosis. The objective of the present study is to report colon metastasis of clear cell carcinoma that required surgery and chemotherapy. Clinical case: We report the case of a 60-year-old male with a history of metastatic renal cancer. His treatment consisted of cytoreductive radical nephrectomy and interferon because of pulmonary disease. He was followed-up for 8 years. Nevertheless, he presented with hematochezia and underwent colonoscopy where a tumor in the spleen was demonstrated. Biopsy reported a clear cell tumor. We performed a left hemicolectomy. Pathology report was clear cell carcinoma with involvement of the colon from the mucosa to serosa. The patient again received interferon. Currently, there is no evidence of tumoral activity and the patient is being followed-up. Conclusions: Renal cancer metastases are most frequent in lung, liver, and bone and less frequent in brain, skin, and soft tissue. Metachromic metastases are identified in the first to second year after nephrectomy in most cases. Survival of patients who present metastasis <1 year after nephrectomy is 33 months vs. patients who present metastasis after 1 year from nephrectomy (55 months). Metastatic clear cell carcinoma requires surgery and immunotherapy. Surgery is the first step for disease control and metastatecomies are indicated in localized disease or when one organ is affected and surgically accessible.


Related Articles

  • Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients. Bordin, Veronica; Giani, Luisa; Meregalli, Sofia; Bukovec, Roberta; Vaghi, Massimo Maria; Mandalà, Mario; Paolorossi, Franco; Ardizzoia, Antonio; Tancini, Gabriele; Barni, Sandro; Frigerio, Franco; Fumagalli, Luca; Bordoni, Arrigo; Valsuani, Gianni; Di Felice, Greta; Lissoni, Paolo // Urologia Internationalis;Jan2000, Vol. 64 Issue 1, p3 

    After the discovery of its essential role in anticancer immunity, IL-2 cancer immunotherapy has shown that comparable results may be obtained with different schedules, including intravenous high-dose IL-2 as a bolus or as a 24-hour intravenous infusion or prolonged subcutaneous injection of...

  • Immunotherapy of Renal Cell Carcinoma. Mickisch, Gerald H. // Urologia Internationalis;Jul99, Vol. 63 Issue 1, p16 

    Treatment of choice for nondisseminated disease is surgery. However, the 5-year survival rates for all stages do not exceed 60%, even in contemporary series. Further improvement will most likely have to await the development of a more effective systemic therapy and the application of combined...

  • Renal Cell Carcinoma. Miller // Urologia Internationalis;Jul99, Vol. 63 Issue 1, p6 

    Diagnosis of renal cell carcinoma (RCC) is established using sonography and confirmation by computed tomography (CT). Due to the widespread use of these imaging techniques for numerous indications, small renal tumors are increasingly detected by chance. As the sensitivity of CT is very high,...

  • Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma. Clark, James M.; Kelley, Benjamin; Titze, Jill; Fung, Henry; Maciejewski, John; Nathan, Sunita; Rich, Elizabeth; Basu, Sanjib; Kaufman, Howard L. // Oncology;Dec2012, Vol. 84 Issue 2, p123 

    Objective: High-dose interleukin-2 (IL-2) is effective immunotherapy for the treatment of metastatic melanoma and renal cell carcinoma (RCC) but has been contraindicated in elderly patients. This study assessed the safety and therapeutic efficacy of high-dose IL-2 in patients ≥65 years of...

  • Agent nearly doubles survival in metastatic RCC. Kuznar, Wayne // Urology Times;Apr2013, Vol. 41 Issue 5, p14 

    The article presents the study of Dr. Asim Amin that investigates the effectiveness of personalized immunotherapy, AGS-003, in boosting the survival rates of patients with metastatic renal cell carcinoma in Orlando, Florida. He did the research on patients who underwent immunotherapy with...

  • Combination of surgery and immunotherapy in metastatic renal cell carcinoma. Mickisch, Gerald H.; Mattes, Roland // World Journal of Urology;Jun2005, Vol. 23 Issue 3, p191 

    The treatment of choice for non-disseminated renal cell cancer (RCC) is surgery. However, the 5-year survival rates for all stages do not exceed 60%, even in contemporary series. Further improvement will most likely have to await the development of a more effective systemic therapy and the...

  • A Novel Preoperative Nomogram for Predicting Lymph Node Invasion in Renal Cell Carcinoma Patients Without Metastasis. Li, Pin; Peng, Cheng; Xie, Yongpeng; Wang, Lei; Gu, Liangyou; Wu, Shengpan; Shen, Donglai; Xuan, Yundong; Ma, Xin; Zhang, Xu // Cancer Management & Research;Nov2019, Vol. 11, p9961 

    Kidney cancer, renal cell carcinoma, lymph node invasion, predictive nomogram.

  • Solitary Contralateral Adrenal Metastasis after Nephrectomy for Renal Cell Carcinoma. Moudouni; En-Nia; Rioux-Leclercq; Guille; Lobel // Urologia Internationalis;May2002, Vol. 68 Issue 4, p295 

    Malignant involvement of the contralateral adrenal gland in cases of renal cell carcinoma is extremely rare. Solitary metachronous metastatic involvement of the contralateral adrenal gland from renal cell carcinoma is rarely diagnosed during life. In fact, clinical signs and symptoms of adrenal...

  • Probability of Ten-Year Survival in Metastatic Renal Cell Carcinoma. Salagierski, Maciej; Salagierski, Marek; Salagierska-Barwińska, Anna; Sosnowski, Marek // Urologia Internationalis;Apr2008, Vol. 80 Issue 3, p335 

    Metastatic renal cancer has a very poor prognosis and constitutes a challenge to uro-oncologists. We present a patient who in the 10 years following the diagnosis of renal cell carcinoma developed nine consecutive metastases in as many sites. He was operated on eleven times in different...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics